develop
countri
bring
futur
challeng
term
health
polici
disabl
rate
unit
state
rate
lead
caus
death
heart
diseas
per
cancer
per
stroke
per
ad
fifth
lead
caus
death
peopl
older
year
age
repres
death
per
year
ad
affect
approxim
million
individu
unit
state
estim
affect
million
disabl
caus
senil
dementia
affect
per
popul
age
year
chapter
outlin
lowto
middleincom
countri
dementia
make
largest
contribut
disabl
median
populationattribut
preval
fraction
follow
stroke
limb
impair
arthriti
depress
eyesight
problem
gastrointestin
impair
western
countri
ad
preval
form
dementia
follow
vascular
dementia
mix
dementia
peopl
older
year
age
may
account
case
differ
form
dementia
pose
sever
challeng
societi
scientif
commun
repres
epidemiolog
problem
socioeconom
psycholog
famili
burden
obscurecomplex
pathogenesi
diagnosi
easi
lack
specif
biomark
treatment
difficult
ineffici
term
econom
burden
approxim
direct
cost
associ
pharmacolog
treatment
gradual
increas
parallel
sever
diseas
canadian
studi
show
mean
total
cost
treat
patient
mild
ad
per
month
compar
per
month
patient
sever
sever
ad
patient
dementia
respond
appropri
convent
drug
onset
advers
drug
reaction
impos
need
drug
neutral
side
effect
thu
multipli
initi
cost
pharmacolog
treatment
health
risk
patient
wimo
et
al
studi
econom
impact
dementia
europ
eufund
eurocod
project
found
total
cost
dementia
countri
estim
billion
per
dementia
patient
per
year
cost
inform
care
correspond
cost
whole
europ
billion
inform
caregiv
cost
largest
cost
compon
account
half
total
societ
cost
depend
countri
ad
sever
addit
relat
problem
direct
indirect
cost
manag
dementia
alarm
abus
inappropri
psychotrop
drug
consumpt
worldwid
antipsychot
medic
taken
elderli
patient
dementia
convent
antipsychot
associ
higher
risk
allcaus
mortal
among
nurs
home
resid
abus
misus
selfprescript
uncontrol
medic
prescript
cn
drug
becom
major
problem
unpredict
consequ
brain
health
pharmacolog
manag
dementia
issu
special
concern
polymed
requir
modul
symptomat
complex
cognit
declin
behavior
chang
psychomotor
deterior
coexist
parallel
grow
bodi
fresh
knowledg
emerg
pathogenesi
dementia
togeth
data
neurogenom
pharmacogenom
cn
disord
incorpor
new
armamentarium
molecular
patholog
genom
medicin
daili
medic
practic
togeth
educ
program
correct
use
drug
must
help
research
clinician
understand
ad
pathogenesi
establish
earli
diagnosi
optim
therapeut
either
prevent
strategi
formal
symptomat
treatment
common
featur
neurodegen
disord
includ
follow
instanc
neuropatholog
hallmark
ad
amyloid
deposit
senil
plaqu
neurofibrillari
tangl
format
neuron
loss
mere
phenotyp
express
pathogen
process
differ
gene
cluster
product
potenti
involv
larg
number
gene
form
structur
architectur
human
genom
express
brain
timedepend
manner
along
lifespan
cellular
complex
cn
differ
cell
type
synaps
neuron
brain
around
synaps
complex
multiprotein
structur
integr
differ
protein
requir
power
technolog
gene
express
profil
still
earli
stage
devoid
technic
obstacl
limit
transcript
gene
measur
differ
cn
region
region
possess
uniqu
transcriptom
fingerprint
independ
age
gender
energi
intak
fewer
gene
affect
age
diet
gender
chang
occur
middl
old
age
gender
energi
restrict
robust
influenc
hippocamp
transcriptom
middleag
anim
promin
function
group
ageand
energysensit
gene
encod
protein
involv
dna
damag
respons
mitochondri
proteasom
function
cell
fate
determin
synapt
vesicl
traffick
introduct
novel
procedur
integr
genom
medicin
protocol
cn
disord
dementia
imper
drug
develop
clinic
practic
order
improv
diagnost
accuraci
optim
therapeut
person
strategi
adapt
complex
case
essenti
depict
clinic
profil
base
specif
biomark
correl
individu
genom
profil
understand
pathophysiolog
cn
disord
dementia
advanc
dramat
last
year
especi
term
molecular
pathogenesi
genet
drug
treatment
cn
disord
also
made
remark
stride
introduct
mani
new
drug
treatment
schizophrenia
depress
anxieti
epilepsi
parkinson
diseas
ad
among
mani
quantit
qualit
import
neuropsychiatr
disord
improv
term
clinic
outcom
howev
fallen
short
expect
onethird
patient
continu
experi
clinic
relaps
unaccept
medicationrel
side
effect
spite
effort
identifi
optim
treatment
regim
one
drug
potenti
reason
histor
setback
might
molecular
patholog
cn
disord
still
poorli
understood
drug
target
inappropri
fit
real
etiolog
diseas
treatment
symptomat
antipathogen
genet
compon
cn
disord
poorli
defin
understand
genomedrug
interact
limit
optim
cn
therapeut
requir
establish
new
postul
regard
cost
medicin
assess
protocol
multifactori
treatment
chronic
disord
implement
novel
therapeut
address
caus
factor
establish
pharmacogenom
strategi
drug
develop
person
therapeut
base
individu
genom
profil
impli
character
five
type
gene
cluster
l
gene
associ
diseas
pathogenesi
l
gene
associ
mechan
action
drug
l
gene
associ
drug
metabol
phase
ii
reaction
l
gene
associ
drug
transport
l
pleiotrop
gene
involv
multifacet
cascad
metabol
reaction
gene
distribut
across
human
genom
screen
associ
ad
past
year
alzgen
databas
gene
potenti
associ
ad
top
ten
decreas
order
import
apo
clu
picalm
potenti
defect
gene
associ
ad
repres
kb
human
genom
integr
kb
highest
proport
relat
total
number
gene
map
singl
chromosom
locat
chromosom
lowest
chromosom
figur
genet
epigenet
defect
identifi
ad
classifi
four
major
categori
mendelian
mutat
suscept
snp
mtdna
mutat
epigenet
chang
mendelian
mutat
affect
gene
directli
link
ad
includ
mutat
amyloid
beta
precursor
protein
app
gene
mutat
presenilin
gene
mutat
presenilin
gene
import
determin
activ
respons
proteolyt
cleavag
app
notch
receptor
protein
mendelian
mutat
rare
ad
mutat
exon
app
gene
appear
frequenc
respect
ad
patient
likewis
microtubuleassoci
protein
tau
mapt
mutat
present
less
case
mutat
gene
confer
specif
phenotyp
profil
patient
dementia
amyloidogen
patholog
associ
app
mutat
tauopathi
associ
mapt
mutat
repres
two
major
pathogen
hypothes
ad
multipl
polymorph
risk
variant
increas
neuron
vulner
prematur
death
see
appendix
among
suscept
gene
apolipoprotein
e
apo
gene
preval
risk
factor
ad
especi
subject
harbor
allel
figur
wherea
carrier
allel
might
protect
dementia
apoerel
pathogen
mechan
also
associ
brain
age
neuropatholog
hallmark
ad
dual
amyloidogenictauopath
theori
ad
domin
pathogen
univers
adrel
neurodegener
divid
research
commun
past
year
nourish
presenc
app
mapt
mutat
small
number
case
earlyonset
ad
nevertheless
theori
explain
ad
pathogenesi
full
consequ
novel
complementari
theori
emerg
recent
past
decad
summari
pathogen
event
ad
given
follow
section
complex
polygenicmultifactori
disord
hundr
polymorph
variant
risk
might
involv
appendix
figur
ad
fulfil
golden
rule
complex
disord
accord
larger
number
genet
defect
distribut
human
genom
earlier
onset
diseas
poorer
therapeut
respons
convent
treatment
convers
smaller
number
pathogen
snp
later
onset
diseas
better
therapeut
respons
differ
pharmacolog
intervent
genet
variat
associ
differ
diseas
interfer
micrornamedi
regul
creat
destroy
modifi
microrna
mirna
bind
site
mirnatarget
variabl
ubiquit
phenomenon
adult
human
brain
may
influenc
gene
express
physiolog
patholog
condit
adrel
snp
interfer
mirna
gene
regul
affect
ad
suscept
signific
interact
includ
target
snp
present
seven
gene
relat
ad
prognosi
mirna
dysregul
mirna
network
contribut
aberr
gene
express
ad
epigenet
factor
emerg
import
mediat
develop
age
genegen
geneenvironment
interact
pathophysiolog
complex
disord
major
epigenet
mechan
dna
methyl
histon
modif
chromatin
remodel
noncod
rna
regul
may
contribut
ad
patholog
vascular
metabol
dysfunct
key
compon
ad
patholog
throughout
cours
diseas
although
common
denomin
vascular
metabol
dysfunct
oxid
stress
genet
factor
cardiovascular
risk
factor
may
also
account
cerebrovascular
damag
present
ad
inherit
polymorph
vascular
suscept
gene
associ
ad
risk
endotheli
dysfunct
implic
crucial
event
develop
ad
breakdown
bloodbrain
barrier
bbb
result
disrupt
tight
junction
transport
lead
increas
leukocyt
transmigr
earli
event
patholog
mani
cn
disord
bbb
breakdown
lead
neuroinflamm
oxid
stress
mitochondri
dysfunct
high
concentr
mitochondria
cerebrovascular
endotheli
cell
might
account
sensit
bbb
oxid
stressor
chronic
brain
hypoperfus
may
suffici
induc
prematur
neuron
death
dementia
vulner
subject
apoerel
chang
cortic
oxygen
hemoglobin
consumpt
evid
reveal
brain
optic
topographi
analysi
reflect
carrier
exhibit
defici
brain
hemodynam
poorer
panneocort
oxygen
carrier
hypoperfus
frontal
pariet
tempor
region
common
find
ad
white
matter
hyperintens
wmh
correl
age
diseas
sever
cerebr
amyloid
angiopathi
caa
account
major
primari
lobal
intracerebr
hemorrhag
ich
among
elderli
repres
caus
spontan
ich
patient
year
age
basi
diseas
process
deposit
format
eventu
destruct
amyloid
plaqu
wall
brain
vessel
predominantli
arteri
exclud
venul
capillari
caa
caaassoci
microhemorrhag
may
also
particip
pathogenesi
ad
deposit
asymptomat
elderli
individu
associ
lobar
mh
lmh
lmh
present
ad
mci
control
neurovascular
dysfunct
ad
lead
reduc
clearanc
across
bbb
accumul
neurotox
peptid
brain
abc
transport
protein
pglycoprotein
pgp
involv
export
brain
blood
pgp
rage
mrna
express
reduc
mice
treat
addit
agerel
decreas
pgp
express
downregul
express
pgp
transport
could
exacerb
intracerebr
accumul
therebi
acceler
neurodegener
ad
cerebr
angiopathi
deposit
senil
neurit
plaqu
hyperphosphoryl
tau
protein
neurofibrillari
tangl
nft
extracellular
intracellular
express
respect
ad
neuropatholog
phenotyp
togeth
select
neuron
loss
hippocamp
neocort
region
plaqu
brain
primari
postmortem
diagnost
criterion
ad
main
compon
senil
plaqu
amino
acid
peptid
gener
proteolyt
cleavag
amyloid
precursor
protein
app
action
betaand
gammasecretas
neurotox
neurotox
relat
aggreg
state
neuron
loss
pathognomon
find
ad
final
common
path
multipl
pathogen
mechan
lead
neurodegener
dementia
atrophi
medial
tempor
lobe
especi
hippocampu
parahippocamp
gyru
consid
ad
predict
structur
brain
biomark
medial
posterior
part
pariet
lobe
seem
preferenti
affect
compar
pariet
lobe
part
imbal
differ
neurotransmitt
glutam
acetylcholin
noradrenalin
dopamin
serotonin
neuropeptid
propos
neurobiolog
basi
behavior
symptom
ad
alter
reuptak
neurotransmitt
vesicular
glutam
transport
vglut
excitatori
amino
acid
transport
eaat
vesicular
acetylcholin
transport
vacht
serotonin
reuptak
transport
sert
dopamin
reuptak
transport
dat
involv
neurotransmiss
imbal
ad
protein
mrna
level
vglut
vacht
sert
reduc
diseas
oxid
damag
classic
pathogen
mechan
neurodegener
greater
brain
tissu
patient
ad
agematch
control
tayler
et
al
studi
time
damag
relat
pathogen
ad
process
antioxid
capac
elev
ad
directli
relat
diseas
sever
indic
braak
tangl
stage
amount
insolubl
accumul
shown
brain
mitochondria
ad
patient
ad
transgen
mous
model
presenc
mitochondria
lead
free
radic
gener
neuron
stress
novel
mitochondri
enzym
presequ
proteas
pre
identifi
mitochondri
matrix
hprep
activ
decreas
ad
human
brain
mitochondri
matrix
ad
transgen
mous
brain
mitochondri
fraction
isol
ad
brain
mice
higher
level
oxid
product
cytochrom
c
oxidas
activ
significantli
reduc
ad
mitochondria
decreas
prep
proteolyt
activ
possibl
due
enhanc
ro
product
may
contribut
accumul
mitochondria
lead
mitochondri
toxic
neuron
death
ad
cholesterol
seem
intim
link
gener
amyloid
plaqu
central
ad
pathogenesi
apo
variant
determin
cholesterol
metabol
divers
form
dyslipoproteinemia
cholesterol
protect
neuron
membran
disrupt
inhibit
betasheet
format
lipid
bilay
jone
et
al
found
signific
overrepresent
associ
signal
pathway
relat
cholesterol
metabol
immun
respons
two
largest
genomewid
associ
studi
load
sever
gene
associ
immun
regul
inflamm
show
polymorph
variant
risk
ad
abnorm
level
divers
cytokin
report
brain
csf
plasma
ad
patient
activ
inflammatori
cascad
consist
demonstr
ad
pathophysiolog
reactiv
microglia
associ
deposit
clearanc
resid
microglia
fail
trigger
effect
phagocyt
respons
clear
deposit
although
mainli
exist
activ
state
oligomer
induc
potent
neurotox
compar
fibrillar
fibril
oligom
increas
microgli
phagocytosi
among
sever
put
neuroinflammatori
mechan
signal
system
central
role
process
ad
level
alter
serum
csf
abnorm
product
inflammatori
factor
may
accompani
progress
mild
cognit
impair
mci
dementia
abnorm
activ
signal
system
repres
increas
express
associ
higher
risk
progress
mci
ad
old
new
theori
suggest
differ
toxic
agent
metal
eg
aluminium
copper
zinc
iron
biotoxin
pesticid
might
contribut
neurodegener
dysfunct
homeostasi
transit
metal
believ
play
role
ad
pathogenesi
mani
novel
pathogen
mechan
potenti
involv
ad
neurodegener
propos
recent
time
moreov
reviv
old
hypothes
exampl
pathogen
player
ad
discuss
includ
ca
hypothesi
insulin
resist
ngf
imbal
glycogen
synthas
advanc
glycat
end
product
age
receptor
rage
efflux
transport
pglycoprotein
pgp
cabl
tyrosin
kinas
posttranscript
protein
alter
compromis
proteasom
system
chaperon
machineri
autophagi
novel
pathway
hypocretin
orexin
cathepsin
b
nogo
receptor
protein
adipocytokin
progenitor
cell
impair
synapt
plastic
anomali
neuron
cell
divis
apoptosi
stem
cell
factor
scf
telomer
shorten
defici
repair
nuclear
mitochondri
dna
damag
microdna
ad
phenotyp
featur
repres
biomark
use
diagnost
predictor
express
pathogen
event
modifi
effect
therapeut
intervent
import
differ
found
ad
popul
compar
healthi
subject
differ
biolog
paramet
includ
blood
pressur
glucos
cholesterol
triglycerid
level
transaminas
activ
hematolog
paramet
metabol
factor
thyroid
function
brain
hemodynam
paramet
brain
map
activ
clinic
differ
clear
sign
comorbid
rather
typic
featur
ad
blood
pressur
valu
glucos
level
cholesterol
level
higher
ad
healthi
elderli
subject
approxim
ad
patient
hypertens
diabet
hypercholesterolem
hypertriglyceridem
patient
exhibit
high
ggt
activ
show
anem
condit
show
abnorm
cerebrovascular
function
character
poor
brain
perfus
abnorm
electroencephalograph
pattern
especi
frontal
tempor
pariet
region
reveal
quantit
eeg
qeeg
computer
map
signific
differ
current
seen
femal
male
indic
effect
gender
phenotyp
express
diseas
fact
preval
dementia
higher
femal
male
year
age
paramet
highli
relev
treat
ad
patient
reflect
concomit
patholog
also
need
therapeut
consider
ad
biomark
differenti
sever
categori
neuropatholog
marker
structur
function
neuroimag
marker
neurophysiolog
marker
eeg
qeeg
brain
map
biochem
marker
bodi
fluid
eg
blood
urin
saliva
csf
genom
marker
structur
function
genom
proteom
metabolom
plaqu
tangl
hippocampu
cortex
still
consid
semin
find
ad
neuropatholog
convent
mean
establish
boundari
amyloidopathi
tauopathi
howev
phenotyp
marker
also
present
normal
brain
case
traumat
brain
injuri
mani
brain
disord
structur
function
neuroimag
techniqu
mri
fmri
pet
spect
essenti
tool
diagnosi
dementia
although
specif
visual
observ
degen
form
dementia
doubt
valu
nevertheless
procedur
irreplac
differenti
diagnosi
characterist
region
impair
ad
involv
mainli
temporopariet
associ
cortic
mesial
tempor
structur
variabl
degre
frontal
associ
cortex
pattern
function
impair
provid
biomark
diagnosi
ad
neurodegen
dementia
clinic
stage
mild
cognit
impair
monitor
progress
healthi
young
apo
carrier
smaller
hippocamp
volum
apo
carrier
differ
hippocamp
morpholog
cognitivelyclin
silent
young
adulthood
render
apo
carrier
prone
later
develop
ad
possibl
lower
reserv
cognit
capac
load
patient
exhibit
select
parahippocamp
white
matter
wm
loss
eoad
patient
experi
widespread
pattern
posterior
wm
atrophi
distinct
region
distribut
wm
atrophi
reflect
topographi
gray
matter
gm
loss
apo
statu
associ
greater
parahippocamp
wm
loss
ad
greater
wm
atrophi
eoad
load
fit
evid
eoad
aggress
form
diseas
fdgpet
quantit
accur
perfus
spect
region
metabol
blood
flow
chang
close
relat
clinic
symptom
area
involv
chang
also
develop
signific
cortic
atrophi
fdgpet
complementari
amyloid
pet
target
molecular
marker
close
relat
current
symptom
fdgpet
expect
play
increas
role
diagnos
patient
earli
stage
ad
clinic
trial
drug
aim
prevent
delay
onset
dementia
function
neuroimag
biomark
becom
popular
introduct
novel
tracer
brain
amyloid
deposit
amyloid
deposit
caus
sever
damag
neuron
mani
year
onset
dementia
via
cascad
sever
downstream
effect
positron
emiss
tomographi
pet
tracer
amyloid
plaqu
desir
earli
diagnosi
ad
particularli
enabl
prevent
treatment
effect
therapeut
avail
amyloid
imag
tracer
flutemetamol
florbetapir
florbetaben
label
f
develop
pet
tracer
current
undergo
formal
clinic
trial
establish
whether
use
accur
imag
fibrillari
amyloid
distinguish
patient
ad
normal
control
diseas
caus
dementia
renew
interest
use
computer
brain
map
diagnost
aid
monitor
tool
ad
electroencephalographi
eeg
studi
ad
show
attenu
averag
power
within
alpha
band
increas
power
theta
band
hz
apo
genotyp
influenc
brain
bioelectr
activ
ad
gener
carrier
tend
exhibit
slower
eeg
pattern
earli
stage
biomark
potenti
interest
includ
cerebrospin
fluid
csf
peripher
level
protein
tau
histamin
interleukin
novel
candid
marker
chitinas
protein
concentr
form
reduc
csf
ad
patient
believ
reflect
ad
patholog
plaqu
brain
act
sink
novel
ctruncat
form
identifi
human
csf
presenc
small
peptid
consist
catabol
amyloid
precursor
protein
cleavag
pathway
increas
dosedepend
respons
inhibitor
treatment
level
unchang
kester
et
al
investig
chang
time
csf
level
amyloidbeta
total
tau
tau
tau
phosphoryl
threonin
isoprostan
neurofila
heavi
nfh
neurofila
light
nfl
tau
tau
phosphoryl
threonin
differenti
diagnosi
group
wherea
isoprostan
nfh
nfl
contrast
effect
followup
time
found
nonspecif
csf
biomark
level
nfl
decreas
level
isoprostan
tau
increas
time
increas
isoprostan
associ
progress
mild
cognit
impair
ad
cognit
declin
contrari
adspecif
marker
nonspecif
csf
biomark
show
chang
time
potenti
use
monitor
diseas
progress
ad
structur
marker
repres
snp
gene
associ
ad
polygen
cluster
analysi
genomewid
studi
gwss
function
marker
attempt
correl
genet
defect
specif
phenotyp
genotypephenotyp
correl
proteom
studi
sever
candid
csf
protein
biomark
assess
neuropatholog
confirm
ad
nondement
nd
elderli
control
nonad
dementia
nadd
marker
select
includ
apolipoprotein
hemopexin
hpx
transthyretin
ttr
pigment
epitheliumderiv
factor
pedf
total
tau
phosphoryl
tau
acid
glycoprotein
haptoglobin
zinc
glycoprotein
apolipoprotein
e
apo
concentr
apo
hpx
differ
significantli
among
ad
nd
nadd
subject
csf
concentr
three
marker
distinguish
ad
nd
subject
sensit
specif
subject
correctli
classifi
comparison
alon
gave
sensit
specif
subject
correctli
classifi
diagnost
discrimin
ad
nadd
concentr
significantli
relat
diagnosi
sensit
specif
carri
allel
associ
signific
decreas
csf
concentr
middleag
older
subject
ad
level
significantli
lower
carrier
compar
noncarri
find
demonstr
signific
age
effect
csf
across
lifespan
also
suggest
decreas
increas
csf
level
acceler
genotyp
middleag
older
adult
normal
cognit
han
et
al
carri
gwa
better
defin
genet
background
normal
cognit
mild
cognit
impair
mci
ad
term
chang
csf
level
ttau
csf
level
decreas
apo
gene
dose
subject
group
ttau
level
tend
higher
among
ad
case
among
normal
subject
aromatas
multipl
snp
locat
chromosom
near
gene
demonstr
strongest
associ
normal
subject
two
gene
found
near
top
snp
report
genet
factor
relat
progress
ad
ad
subject
apo
genotyp
associ
elev
ttau
level
genotyp
associ
elev
ttau
level
bloodbas
marker
reflect
core
patholog
featur
ad
presymptomat
individu
like
acceler
develop
diseasemodifi
treatment
thambisetti
et
al
perform
proteom
analysi
discov
plasma
protein
associ
brain
burden
nondement
older
individu
panel
plasma
protein
spot
effect
discrimin
individu
high
low
brain
mass
spectrometri
identifi
protein
mani
establish
role
clearanc
includ
strong
signal
apo
strong
associ
observ
plasma
apo
concentr
burden
medial
tempor
lobe
target
voxelbas
analysi
local
associ
hippocampu
entorhin
cortex
apo
carrier
also
show
greater
level
sever
brain
region
rel
noncarri
peripher
concentr
apo
protein
apo
genotyp
may
relat
earli
neuropatholog
chang
brain
region
vulner
ad
patholog
even
nondement
elderli
modern
therapeut
strategi
ad
aim
interf
main
pathogen
mechan
potenti
involv
ad
box
start
earli
neuropharmacolog
ad
domin
acetylcholinesteras
inhibitor
repres
tacrin
donepezil
rivastigmin
galantamin
memantin
partial
nmda
antagonist
introduc
treatment
sever
dementia
first
clinic
trial
immunotherapi
reduc
amyloid
burden
senil
plaqu
withdrawn
due
sever
adr
initi
promis
inhibitor
novel
vaccin
devoid
sever
side
effect
past
year
relev
drug
candid
dazzl
scientif
commun
capac
halt
diseas
progress
howev
larg
number
novel
therapeut
strategi
pharmacolog
treatment
ad
postul
appar
effect
preclin
studi
see
box
two
main
modal
immunotherapi
ad
passiv
immunotherapi
administr
monoclon
antibodi
activ
immun
antigen
synthet
fragment
bound
carrier
protein
thu
avoid
potenti
problem
associ
mount
tcell
respons
directli
new
approachdeliv
novel
immunogenadjuv
manner
consist
contain
liposom
administ
transgen
mice
detect
adlik
patholog
brainha
recent
develop
result
novel
vaccin
indic
activ
immun
significantli
prevent
revers
progress
adlik
patholog
also
clear
prototyp
neuropatholog
hallmark
transgen
mice
new
approach
strongli
induc
tcell
bcell
microgli
immun
respons
activ
avoid
inflammatori
reaction
rational
amyloid
immunotherapi
ad
base
follow
assumpt
l
plaqu
aggreg
protofibrillar
oligomer
precursor
contain
immunolog
neoepitop
absent
fulllength
amyloid
precursor
protein
app
well
solubl
proteolyt
deriv
restrict
brain
tissu
consequ
immunotherapi
design
select
target
patholog
neoepitop
present
oligom
protofibril
fibril
caus
autoimmun
diseas
unaffect
tissu
throughout
organ
l
buildup
preced
neurodegener
function
loss
either
prevent
format
remov
expect
result
slow
prevent
neurodegener
l
caus
format
neurofibrillari
tangl
vivo
vitro
remov
prevent
buildup
potenti
correct
toxic
also
prevent
format
neurofibrillari
tangl
l
conform
chang
endogen
occur
protein
format
insolubl
aggreg
commonli
associ
neurodegener
brain
diseas
remov
prevent
patholog
protein
aggreg
also
therapeut
goal
principl
immunotherapi
l
immunotherapi
work
experiment
anim
initi
clinic
trial
activ
immun
passiv
antibodi
transfer
consist
reduc
brain
load
improv
memori
impair
protect
neuron
degener
mani
independ
experi
use
differ
mous
model
primat
sinc
immunotherapi
limit
clearanc
effect
tau
aggreg
dystroph
neurit
develop
altern
therapi
directli
target
patholog
tau
becom
crucial
increas
level
tau
oligom
observ
earli
stage
ad
prior
detect
neurofibrillari
tangl
nft
form
aggreg
accumul
microtubuleassoci
protein
tau
sever
approach
taken
treat
ad
target
tau
follow
inhibit
tau
hyperphosphoryl
kinas
inhibitor
solubl
aggreg
tau
format
also
prevent
relat
motor
deficit
activ
proteolyt
pathway
degrad
action
calpain
puromycinsensit
aminopeptidas
stabil
microtubul
treat
tauopathi
function
bind
stabil
microtubul
mtbind
protein
tau
paclitaxel
drug
proven
effect
restor
affect
axon
transport
motor
impair
tau
clearanc
immunotherapi
case
tau
activ
vaccin
use
phosphoryl
antigen
tau
fragment
associ
neurofibrillari
tangl
result
effici
reduct
solubl
insolubl
tau
activ
fragment
reduc
phosphoryl
nft
adlik
mous
brain
preclin
studi
shown
clear
evid
immun
therapi
provid
protect
revers
patholog
effect
ad
transgen
mous
model
strategi
seem
improv
cognit
perform
immun
addit
caus
effect
reduct
patholog
recent
immun
studi
proven
fragment
peptid
bound
polylysin
activ
immun
respons
diminish
adlik
patholog
app
transgen
mice
result
reinforc
notion
immuneconjug
approach
effect
mean
immunotherapi
also
entir
peptid
necessari
efficaci
accord
hypothesi
specif
antibodi
direct
aminotermin
andor
central
region
amyloid
peptid
provid
benefici
protect
amyloid
patholog
passiv
immun
studi
also
conduct
promis
experiment
result
show
humor
respons
alon
without
cellular
respons
suffici
reduc
burden
revers
memori
deficit
among
drug
vaccin
current
develop
treat
patholog
effect
ad
promis
bapineuzumab
solanezumab
solanezumab
monoclon
antibodi
rais
recogn
epitop
core
amyloid
peptid
bind
select
solubl
low
affin
fibrillar
form
thu
present
fewer
advers
event
bapineuzumab
bind
amyloid
plaqu
strongli
solubl
monoclon
antibodi
properti
differ
bapineuzumab
specif
target
free
carboxyterminu
bind
equal
high
affin
monom
oligom
fibril
target
nterminu
specif
antibodi
present
pool
prepar
intraven
immunoglobulin
ivig
igiv
alreadi
approv
fda
treatment
varieti
neurolog
condit
current
result
studi
shown
ivig
treatment
may
also
efficaci
altern
approach
treatment
ad
neuropatholog
avoid
strong
effect
adjuv
tcell
epitop
cterminu
consist
short
ntermin
fragment
attach
viruslik
particl
addit
adjuv
therapeut
agent
current
phase
ii
trial
affiri
test
two
short
administ
aluminum
hydroxid
adjuv
mimic
free
nterminu
therefor
caus
crossreact
nativ
peptid
phase
trial
term
prevent
therapeut
treatment
vaccin
show
first
time
effect
combin
liposom
immunogenadjuv
antigen
induc
effect
immunolog
respons
combin
antiinflammatori
effect
preclin
studi
use
transgen
mice
vaccin
immun
process
shown
mark
posit
effect
prevent
therapeut
treatment
reduc
amyloidosisinduc
inflamm
effect
immunomodul
moreov
vaccin
prove
stimul
innat
immun
enabl
effect
phagocytosi
clear
amyloid
neurofibrillari
tangl
among
major
hallmark
adlik
neuropatholog
observ
vaccin
current
develop
recent
studi
open
new
perspect
immun
approach
ad
patholog
particular
genegunmedi
genet
immun
gene
show
selftoler
broken
order
produc
humor
respons
peptid
minim
cellular
respons
ad
patient
may
take
differ
drug
per
day
treatment
dementiarel
symptom
includ
memori
declin
convent
antidementia
drug
neuroprotect
behavior
chang
antidepress
neurolept
sed
hypnot
function
declin
drug
may
also
taken
treatment
concomit
patholog
epilepsi
cardiovascular
cerebrovascular
disord
parkinson
hypertens
dyslipidemia
anemia
arthrosi
etc
coadministr
sever
drug
may
caus
side
effect
adr
ad
patient
case
requir
hospit
patient
behavior
deterior
psychomotor
function
sever
alter
polypharmaci
princip
caus
iatrogen
effect
inappropri
combin
drug
genom
background
patient
respons
hisher
pharmacogenom
outcom
pharmacogenom
account
variabl
pharmacokinet
pharmacodynam
gene
involv
pharmacogenom
respons
drug
ad
fall
five
major
categori
clinic
trial
dementia
apo
use
gene
refer
pharmacogenom
ad
sever
studi
indic
presenc
allel
differenti
affect
qualiti
extent
drug
respons
ad
patient
treat
cholinerg
enhanc
tacrin
donepezil
galantamin
rivastigmin
neuroprotect
compound
nootrop
endogen
nucleotid
cdpcholin
immunotrophin
anapso
neurotroph
factor
cerebrolysin
rosiglitazon
combin
therapi
howev
controversi
result
frequent
found
due
methodolog
problem
studi
design
patient
recruit
clinic
trial
major
conclus
studi
carrier
worst
respond
convent
treatment
apo
genotyp
integr
bigen
cluster
therapeut
respons
combin
therapi
analyz
ad
patient
becom
clear
presenc
genotyp
abl
convert
pure
extens
metabol
em
full
poor
respond
convent
treatment
indic
exist
power
influenc
homozyg
genotyp
drugmetabol
capac
pure
em
addit
clear
accumul
genotyp
observ
among
poor
pm
ultrarapid
metabol
um
gene
associ
mechan
action
cn
drug
encod
receptor
enzym
neurotransmitt
psychotrop
drug
act
ligand
agonist
antagonist
enzym
modul
substrat
inhibitor
induc
neurotransmitt
regul
releas
reuptak
inhibitor
case
convent
antidementia
drug
tacrin
donepezil
rivastigmin
galantamin
cholinesteras
inhibitor
memantin
partial
nmda
antagonist
tabl
drug
metabol
includ
phase
reaction
ie
oxid
reduct
hydrolysi
phase
ii
conjug
reaction
ie
acetyl
glucuronid
sulphat
methyl
tabl
princip
enzym
polymorph
variant
involv
phase
reaction
follow
cytochrom
monooxygenas
epoxid
hydrolas
esteras
nadphquinon
oxidoreductas
dpd
dihydropyrimidin
dehydrogenas
adh
alcohol
dehydrogenas
aldh
aldehyd
dehydrogenas
major
enzym
involv
phase
ii
reaction
includ
ugt
uridin
glucuronosyl
transferas
tpmt
thiopurin
methyltransferas
comt
catecholomethyltransferas
hmt
histamin
methyltransferas
st
sulfotransferas
gsta
glutathion
stransferas
gstp
gstt
gstm
nacetyl
transferas
other
tabl
among
enzym
relev
pharmacogenet
cn
drug
tabl
approxim
neurolept
major
substrat
enzym
antidepress
major
substrat
enzym
benzodiazepin
major
substrat
enzym
cyp
enzym
exhibit
ontogen
age
sex
circadian
ethnicrel
differ
dementia
cn
disord
cyp
genom
import
issu
sinc
practic
patient
dementia
daili
consum
psychotrop
furthermor
acetylcholinesteras
inhibitor
prescrib
antidementia
drug
worldwid
metabol
via
cyp
enzym
tabl
cyp
enzym
display
highli
signific
ethnic
differ
indic
enzymat
capac
protein
vari
depend
upon
polymorph
variant
present
code
cyp
gene
practic
consequ
genet
variat
drug
differenti
metabol
accord
genet
profil
subject
individu
pharmacogenom
profil
known
pharmacodynam
respons
potenti
predict
cornerston
pharmacogenet
regard
gene
respect
protein
product
deserv
special
consider
kb
gene
exon
map
four
rna
transcript
bp
express
brain
liver
spleen
reproduct
system
major
protein
kda
aa
identifi
transport
enzym
cytochrom
subfamili
iid
multigen
cytochrom
superfamili
mixedfunct
monooxygenas
cytochrom
protein
monooxygenas
catalyz
mani
reaction
involv
drug
metabol
synthesi
cholesterol
steroid
lipid
local
endoplasm
reticulum
known
metabol
mani
commonli
prescrib
drug
current
psychotrop
substrat
includ
debrisoquin
adrenergicblock
drug
spartein
propafenon
antiarrhythm
drug
amitryptilin
antidepress
highli
polymorph
popul
allel
variant
repres
ten
import
differ
allel
result
extens
intermedi
poor
ultrarapid
metabol
phenotyp
character
normal
intermedi
decreas
multipli
abil
metabol
enzym
substrat
respect
hepat
cytochrom
system
respons
first
phase
metabol
elimin
numer
endogen
exogen
molecul
ingest
chemic
enzym
convert
substanc
electrophil
intermedi
conjug
phase
ii
enzym
eg
udp
glucuronosyltransferas
nacetyltransferas
hydrophil
deriv
excret
accord
databas
world
guid
drug
use
pharmacogenom
drug
substrat
inhibitor
induc
healthi
subject
extens
metabol
em
account
popul
intermedi
metabol
im
account
poor
metabol
pm
ultrarapid
metabol
um
remark
worldwid
interethn
differ
exist
frequenc
pm
um
phenotyp
averag
approxim
world
popul
belong
pm
categori
european
polynesian
african
show
highest
rate
pm
wherea
orient
show
lowest
frequenc
pm
among
middl
eastern
popul
asian
american
rang
gene
duplic
rel
infrequ
among
northern
european
east
africa
frequenc
allel
duplic
high
europ
northsouth
gradient
frequenc
pm
pm
southern
european
countri
pm
northern
latitud
ad
em
im
pm
um
respect
vascular
dementia
respect
figur
accumul
adrel
risk
gene
pm
um
em
im
best
respond
pm
um
worst
respond
combin
therapi
cholinesteras
inhibitor
neuroprotect
vasoact
substanc
pharmacogenet
respons
ad
appear
depend
network
activ
gene
involv
drug
metabol
gene
involv
ad
pathogenesi
gene
kb
exon
map
rna
transcript
bp
mainli
express
hepatocyt
protein
kda
aa
identifi
drug
act
substrat
major
minor
inhibitor
weak
moder
strong
induc
enzym
snp
phenotyp
figur
control
popul
pm
repres
im
em
ad
pm
im
em
respect
vascular
dementia
respect
figur
metabol
drug
act
substrat
major
minor
inhibitor
weak
moder
strong
induc
enzym
snp
identifi
gene
wildtyp
clinic
relev
concern
polymorph
ad
case
em
im
um
unlik
human
evid
null
allel
construct
genet
map
integr
preval
polymorph
variant
trigen
cluster
yield
differ
haplotypelik
profil
frequent
trigen
genotyp
ad
popul
trigen
genotyp
repres
differ
pharmacogenet
phenotyp
accord
trigen
cluster
patient
show
pure
phenotyp
pure
pure
worst
possibl
phenotyp
impli
onequart
popul
normal
process
drug
metabol
via
approxim
drug
current
use
take
consider
data
avail
might
infer
least
ad
popul
may
exhibit
abnorm
metabol
cholinesteras
inhibitor
andor
drug
undergo
oxid
via
enzym
approxim
popul
cluster
show
ultrarapid
metabol
requir
higher
dose
cholinesteras
inhibitor
order
reach
therapeut
threshold
cluster
exhibit
poor
metabol
display
potenti
advers
event
low
dose
take
account
approxim
therapeut
outcom
depend
pharmacogenom
criteria
eg
pathogen
mechan
associ
adrel
gene
postul
pharmacogenet
pharmacogenom
factor
respons
therapeut
respons
efficaci
ad
patient
treat
convent
drug
abc
genesespeci
atpbind
cassett
subfamili
b
member
multidrug
resist
mdr
gene
familyencod
protein
essenti
drug
metabol
transport
multidrug
efflux
transport
pgp
multidrug
resistanceassoci
protein
breast
cancer
resistanceprotein
bcrp
locat
endotheli
cell
line
brain
vasculatur
play
import
role
limit
movement
substanc
brain
enhanc
efflux
brain
transport
also
cooper
phase
iphas
ii
metabol
enzym
elimin
drug
metabolit
major
featur
capac
recogn
drug
belong
unrel
pharmacolog
class
redund
singl
molecul
act
substrat
differ
transport
ensur
effici
neuroprotect
xenobiot
invas
pharmacolog
induct
abc
gene
express
mechan
drug
interact
may
affect
substrat
upregul
transport
overexpress
mdr
transport
confer
resist
anticanc
agent
cn
drug
also
import
cn
pharmacogenom
transport
encod
gene
solut
carrier
superfamili
slc
solut
carrier
organ
slco
transport
famili
respons
transport
multipl
endogen
exogen
compound
includ
folat
urea
monoamin
aminoacid
organ
anion
transport
oat
belong
solut
carrier
slc
famili
also
express
bbb
regul
excret
endogen
exogen
organ
anion
cation
transport
amino
acid
diand
tripeptid
mediat
number
differ
transport
famili
bulk
oligopeptid
transport
attribut
activ
member
superfamili
peptid
transport
peptidehistidin
transport
abc
slc
transport
express
bbb
may
cooper
regul
passag
differ
molecul
brain
polymorph
variant
abc
slc
gene
may
also
associ
pathogen
event
cn
disord
drugrel
safeti
efficaci
complic
apo
prototyp
paradigm
pleiotrop
gene
multifacet
activ
physiolog
patholog
condit
apo
consist
associ
amyloid
plaqu
marker
ad
may
influenc
ad
patholog
interact
app
metabol
accumul
enhanc
hyperphosphoryl
tau
protein
nft
format
reduc
cholin
acetyltransferas
activ
increas
oxid
process
modifi
inflammationrel
neuroimmunotroph
activ
glial
activ
alter
lipid
metabol
lipid
transport
membran
biosynthesi
sprout
synapt
remodel
induc
neuron
apoptosi
address
complex
misfold
aggreg
initi
toxic
cascad
result
ad
petrlova
et
al
develop
acid
spinlabel
peptid
observ
isoformdepend
interact
apo
protein
oligom
bind
involv
ctermin
domain
apo
report
much
greater
respons
conform
marker
display
higher
affin
capac
toxic
oligom
apo
polymorph
ad
risk
larg
attribut
reduc
abil
function
clearanc
vehicl
toxic
form
mapt
apo
involv
pathogen
mechan
ad
mapt
genotyp
apo
allel
lead
rapid
progress
dementia
among
mci
subject
probabl
mediat
increas
rate
tau
brain
deposit
distribut
apo
genotyp
iberian
peninsula
follow
figur
frequenc
similar
europ
western
societi
clear
accumul
carrier
among
patient
ad
vascular
dementia
compar
control
figur
differ
apo
genotyp
confer
specif
phenotyp
profil
ad
patient
profil
may
add
risk
benefit
patient
treat
convent
drug
mani
instanc
clinic
phenotyp
demand
administr
addit
drug
increas
complex
therapeut
protocol
studi
design
defin
apoerel
ad
phenotyp
sever
conclus
drawn
shown
box
major
phenotyp
featur
clearli
illustr
biolog
disadvantag
homozygot
potenti
consequ
patient
may
experi
receiv
pharmacolog
treatment
ad
andor
concomit
patholog
follow
list
describ
pharmacogenom
common
antidementia
drug
tabl
donepezil
central
activ
revers
acetylcholinesteras
inhibitor
increas
acetylcholin
avail
synapt
transmiss
cn
therapeut
respons
donepezil
influenc
pathogen
gene
variant
apo
chat
well
mechanist
gene
polymorph
variant
chat
ach
bche
major
substrat
ach
ugt
inhibit
ach
bche
transport
galantamin
revers
competit
acetylcholinesteras
inhibitor
lead
increas
concentr
acetylcholin
cholinerg
synaps
also
modul
nicotin
acetylcholin
receptor
may
increas
glutam
serotonin
level
apo
app
ach
bche
variant
may
potenti
influenc
galantamin
efficaci
safeti
galantamin
major
substrat
inhibitor
ach
bche
ad
case
harbor
genotyp
wave
activ
earli
stage
diseas
brain
hemodynam
reflect
reduc
brain
blood
flow
veloc
increas
pulsatil
resist
indic
significantli
wors
carrier
gener
compar
carrier
brain
hypoperfus
neocort
oxygen
also
defici
carrier
carrier
rivastigmin
cholinesteras
inhibitor
increas
acetylcholin
cn
revers
inhibit
hydrolysi
cholinesteras
apo
app
chat
ach
bche
mapt
variant
may
affect
pharmacokinet
pharmacodynam
tacrin
first
fdaapprov
antidementia
drug
use
stop
due
hepatotox
tacrin
cholinesteras
inhibitor
elev
acetylcholin
cerebr
cortex
slow
degrad
acetylcholin
ach
bche
apo
mthfr
lepr
variant
may
affect
therapeut
toxic
effect
tacrin
major
substrat
minor
substrat
transport
via
inhibitor
ach
bche
memantin
nmethyldaspart
nmda
receptor
antagonist
bind
preferenti
nmda
receptoroper
cation
channel
may
act
block
action
glutam
mediat
part
nmda
receptor
also
antagonist
sever
pathogen
apo
mapt
mechanist
gene
variant
may
influenc
therapeut
effect
memantin
strong
inhibitor
weak
inhibitor
studi
use
multifactori
approach
also
shown
divers
pharmacogenom
factor
may
influenc
efficaci
safeti
one
studi
patient
dementia
receiv
follow
three
month
patient
chronic
defici
iron
folic
acid
ngml
vitamin
b
pgml
receiv
addit
supplement
iron
mgday
folic
acid
mgday
b
complex
vitamin
b
mg
day
b
mgday
b
mgday
b
nicotinamid
mgday
respect
maintain
stabl
level
serum
iron
folic
acid
ngml
vitamin
b
level
pgml
order
avoid
neg
influenc
metabol
factor
cognit
patient
hypertens
mmhg
receiv
enalapril
mgday
studi
basal
mmse
score
differ
carrier
respect
p
p
p
vs
p
vs
p
best
respond
p
p
carrier
p
patient
harbor
genotyp
show
signific
improv
respons
rate
genotyp
follow
systol
blood
pressur
sbp
significantli
reduc
patient
p
genotyp
p
diastol
blood
pressur
exhibit
similar
pattern
p
hdlcholesterol
level
significantli
decreas
p
p
signific
chang
patient
genotyp
contrast
ldlcholesterol
level
show
chang
ident
observ
total
cholesterol
similar
differ
among
genotyp
baselin
almost
ident
decreas
level
treatment
p
p
p
p
sardilipin
natur
product
extract
marin
speci
sardina
pilchardu
mean
nondenatur
biotechnolog
procedur
main
chemic
compound
lipoprotein
whose
micel
structur
probabl
mimic
physiolog
lipoprotein
involv
lipid
metabol
preclin
studi
sardilipinha
shown
effect
reduc
blood
cholesterol
cho
triglycerid
tg
uric
acid
ua
glucos
glu
level
well
liver
alanin
aminotransferas
alt
aspart
aminotransferas
ast
activ
lymphocyt
microglia
activ
induc
antioxid
effect
mediat
superoxid
dismutas
activ
improv
cognit
function
accord
result
appear
therapeut
respons
patient
dyslipidemia
sardilipin
apoerel
best
respond
patient
patient
apo
genotyp
show
hypolipidem
respons
novel
compound
patient
dementia
effect
sardilipin
similar
observ
patient
chronic
dyslipidemia
suggest
lipidlow
properti
sardilipin
apoedepend
figur
make
ad
global
health
prioriti
come
year
conceptu
procedur
chang
need
sever
ground
polit
administr
econom
legal
ethic
industri
regulatori
educ
issu
novel
biomark
genom
proteom
molecular
neuroimag
diagnost
aid
innov
therapeut
pharmacogenom
clinic
practic
optim
therapeut
select
prevent
plan
popul
risk
disharmoni
concern
public
government
interest
dementia
social
medic
econom
implic
diagnosi
manag
dementia
dissimilar
europ
north
america
latin
america
asia
africa
oceania
economiccultur
statu
countri
develop
versu
develop
particular
epidemiolog
age
dementia
latitud
nation
standard
educ
health
prioriti
infecti
diseas
versu
degen
diseas
qualiti
effici
medic
servic
condit
factor
invest
invest
nation
resourc
dementia
health
prioriti
educ
program
intern
guidelin
consensu
protocol
manag
dementia
necessari
global
harmon
profession
differ
countri
speak
conceptu
languag
improv
costeffect
ratio
mani
legal
issu
eg
inform
consent
lawsuit
testament
tutorship
ethic
issu
eg
clinic
trial
use
genet
inform
institution
deserv
attent
order
human
end
life
frail
condit
dement
patient
surviv
updat
regulatori
issu
also
matter
deep
concern
regulatori
aspect
drug
develop
univers
notabl
peculiar
european
union
ema
unit
state
fda
japan
koseisho
cost
dementia
fulli
assum
european
popul
european
author
must
take
account
circumst
health
reform
implement
come
year
genom
transcriptom
proteom
metabolom
revolution
medicin
next
decad
genet
test
gain
accept
among
physician
patient
differ
countri
although
american
european
japanes
differ
notabl
knowledg
belief
attitud
regard
genet
test
ad
valid
protocol
genom
screen
contribut
implement
structur
genom
function
genom
proteom
diagnost
aid
therapeut
target
accur
diagnosi
ad
demand
use
reliabl
biomark
routin
protocol
reason
price
level
specif
secret
cellular
signal
protein
cerebrospin
fluid
plasma
correl
patholog
chang
ad
brain
therefor
proteom
analysi
level
use
discov
said
biomark
like
best
biomark
result
combin
genom
transcriptom
proteom
analys
bodi
fluid
measur
biomark
correl
brain
imag
marker
cognit
perform
new
initi
prevent
dementia
global
versu
select
prevent
also
emerg
togeth
new
insight
role
nutrit
nutrigenom
brain
function
neurodegener
term
prevent
must
taken
consider
neuron
death
accumul
start
mani
year
onset
diseas
prevent
strategi
select
protect
popul
risk
purpos
accur
biomark
essenti
surrog
marker
need
facilit
primari
prevent
without
doubt
highest
prioriti
come
decad
intens
search
novel
therapeut
option
form
symptomat
treatment
prevent
strategi
past
failur
must
studi
research
pharmaceut
industri
order
avoid
unnecessari
expens
redund
trial
lead
nowher
combin
treatment
requir
evalu
sophist
strategi
dual
combin
administr
psychotrop
drug
dement
patient
reduc
predict
pharmacogenet
marker
minim
side
effect
cerebrovascular
risk
cognit
deterior
prioriti
area
pharmacogenet
research
predict
seriou
advers
drug
reaction
adr
determin
efficaci
variat
necessari
cn
disord
dementia
cope
efficaci
safeti
issu
associ
current
psychotrop
antidementia
drug
well
new
cn
drug
regard
futur
pharmacogenom
practic
disciplin
sever
issu
address
l
educ
physician
medic
genom
pharmacogenom
fundament
less
clinician
familiar
genom
scienc
l
genom
screen
gene
cluster
involv
pharmacogenom
outcom
must
becom
clinic
routin
without
genet
test
pharmacogenet
l
patient
must
carrier
pharmacogenet
card
indic
kind
drug
hesh
take
medic
hesh
avoid
l
regulatori
agenc
request
pharmacogenet
data
pharmaceut
industri
appli
drug
approv
l
pharmacogenet
data
must
incorpor
patient
inform
leaflet
pharmaceut
vade
mecum
l
new
guidelin
daili
praxi
given
world
guid
drug
use
pharmacogenom
promot
understand
relationship
drug
gene
make
drug
prescript
truli
person
ad
major
health
problem
come
high
cost
societi
clinic
entiti
ad
polygeniccomplex
disord
mani
differ
gene
cluster
may
involv
gene
screen
date
belong
differ
proteom
metabolom
pathway
potenti
affect
ad
pathogenesi
repres
accumul
deposit
senil
plaqu
intracellular
nft
hyperphosphoryl
tau
neuron
loss
presenc
allel
apolipoprotein
e
gene
seem
major
risk
factor
degen
vascular
dementia
apo
variant
directli
involv
ad
pathogenesi
multipl
level
specif
biomark
structur
function
genom
marker
proteom
marker
bodi
fluid
neuroimag
marker
need
accur
ad
diagnosi
current
pharmacolog
treatment
ad
cholinesteras
inhibitor
donepezil
rivastigmin
galantamin
memantin
costeffect
moreov
overus
psychotrop
drug
patient
dementia
contribut
deterior
cognit
psychomotor
function
old
treatment
address
memori
impair
new
treatment
orient
halt
diseas
progress
interf
accumul
nft
format
oxid
stress
neuroinflamm
cerebrovascular
damag
past
year
divers
candid
drug
investig
ad
model
one
reach
market
sinc
popul
extens
metabol
drug
metabol
via
enzym
seem
reason
use
pharmacogenom
procedur
way
optim
ad
therapeut
thu
reduc
adr
unnecessari
cost
therapeut
respons
convent
drug
patient
ad
genotypespecif
carrier
shown
worst
respond
apo
may
cooper
pleiotrop
gene
metabol
drug
hepat
function
know
pharmacogenom
profil
patient
requir
treatment
antidementia
drug
andor
psychotrop
drug
current
use
may
abl
achiev
follow
benefit
l
identifi
candid
patient
ideal
genom
profil
receiv
particular
drug
l
adapt
dose
case
accord
condit
em
im
pm
um
limit
occurr
direct
side
effect
case
l
reduc
drug
interact
avoid
administr
inhibitor
induc
abl
modifi
normal
enzymat
activ
particular
substrat
l
enhanc
efficaci
l
elimin
unnecessari
cost
pharmaceut
direct
cost
deriv
consequ
inappropri
drug
select
overmed
mitig
adr
appendix
